Louisiana State Employees Retirement System Acquires New Shares in ADMA Biologics Inc $ADMA

Louisiana State Employees Retirement System acquired a new position in ADMA Biologics Inc (NASDAQ:ADMA) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 105,500 shares of the biotechnology company’s stock, valued at approximately $951,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Summit Securities Group LLC purchased a new position in shares of ADMA Biologics during the 4th quarter worth $29,000. Optima Capital LLC acquired a new position in ADMA Biologics in the fourth quarter valued at about $36,000. iSAM Funds UK Ltd acquired a new position in ADMA Biologics in the third quarter valued at about $34,000. RiverPark Advisors LLC purchased a new position in ADMA Biologics during the third quarter worth about $35,000. Finally, Morse Asset Management Inc purchased a new position in ADMA Biologics during the fourth quarter worth about $44,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman bought 12,500 shares of ADMA Biologics stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the acquisition, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.90% of the company’s stock.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Bronstein, Schall, Glancy Prongay, Berger Montague, KSF, Faruqi & Faruqi, and Kirby McInerney, issued reminders about the ongoing ADMA Biologics securities class action and the approaching August 10 lead plaintiff deadline. Article: Rosen, National Investor Counsel, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ADMA
• Neutral Sentiment: The complaints allege violations of federal securities laws and claim investors who bought ADMA shares during the class period may have suffered losses, which keeps legal risk in focus. Article: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Neutral Sentiment: One filing specifically alleges ADMA made misrepresentations about its revenue sources, adding to concerns about the company’s prior disclosures. Article: ADMA Shareholder News: ADMA Biologics Accused of Making Misrepresentations about its Revenue Sources in Securities Fraud Class Action

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ADMA shares. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Canaccord Genuity Group lowered their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Zacks Research downgraded shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. Finally, Raymond James Financial began coverage on ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, ADMA Biologics has an average rating of “Hold” and a consensus price target of $19.67.

ADMA Biologics Stock Performance

ADMA opened at $8.95 on Monday. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $20.46. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of 13.16 and a beta of 0.73. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. The business has a fifty day moving average price of $8.70 and a 200 day moving average price of $12.96.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting the consensus estimate of $0.19. The company had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.ADMA Biologics’s revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.11 EPS. Sell-side analysts expect that ADMA Biologics Inc will post 0.82 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.